Intel closed the week at $86.30 — down 18% in five sessions and 33% below the June 30 peak — as the market continues to price the Ohio foundry commitment as a liability, not an asset.
The price action has entered a new, more uncomfortable phase. The stock was at $92.32 when Friday's previous note identified the central contradiction: analysts raising targets into a falling stock. That contradiction has now sharpened. INTC has shed another $6 since Sunday. It is now trading below Morgan Stanley's $84 Equal-Weight target — the most bearish of the post-earnings revisions from a bellwether firm — and below JPMorgan's $85 Underweight mark as well. The consensus mean of $115.27 implies a 33% premium to Tuesday's close, but the gap between where analysts have their numbers and where the stock actually trades has not historically been a catalyst by itself. The company that was briefly the AI comeback story of 2026 has now given back essentially the entire year-to-date re-rating.
Options positioning has turned more defensive than at any point in recent weeks. The put/call ratio reached 0.99 on Tuesday — roughly 1.6 standard deviations above its 20-day average of 0.96 and the highest reading since June 18, when the stock was still above $130. This is the sharpest pivot in sentiment direction since the pre-earnings window, when the PCR was running below 0.93 and options traders were net bullish on a recovery. That call-heavy tilt has now fully reversed. The 52-week PCR range runs from 0.61 to 1.16, so the reading is not extreme in absolute terms — but the direction of travel, from the bullish end toward the bearish end in under two weeks, is notable. Short interest, by contrast, remains structurally low at 2.62% of free float and barely moved on the week (down 0.12%). Availability is effectively uncapped — billions of shares sit in the lending pool — and cost to borrow, while up 13% on the week to 0.35%, is still among the cheapest borrows in the semiconductor sector. Bears are not pressing shorts here; the selling is coming from holders, not new short positions.
The Street's response to earnings has produced one of the more unusual analyst configurations Intel has seen. Almost every firm raised targets post-Q2 — Baird to $125, DA Davidson to $100, Truist to $108, Wedbush to $98, Roth Capital to $120 — yet almost none upgraded conviction on the rating. Morgan Stanley held Equal-Weight at $84, JPMorgan held Underweight at $85, and Stifel actually cut its target to $110 from $120. B of A Securities maintained its lone Buy at $160. The result is a consensus that is nominally bullish — 12 Buy ratings, consensus rating "buy" — but structurally cautious, with the majority of covering analysts rating the stock Hold or below. The bull case rests on strong revenue momentum, gross margin recovery, and the potential for Intel Foundry to convert pipeline interest into committed external customers. The bear case is more immediate: 14A remains a 2028-2029 story, the Ohio capex commitment is $20 billion in real capital leaving the balance sheet now, and there is no near-term catalyst to close the gap between target prices and where the stock actually clears. EV/EBITDA has compressed to 17.7x, down more than 4x over 30 days. PE at 47.9x — roughly half what it was a month ago — reflects just how violently the multiple has re-rated alongside the price.
The semiconductor peer group offered no shelter this week. AMD fell 8.1% on the day and 16.5% on the week. MXL dropped 9.1% on Tuesday alone, down 31.5% for the week. MTSI and FORM fell 5.3% and 10.7% respectively. The sector is under broad pressure, which makes it harder to isolate Intel-specific signal from macro noise — but Intel's week-to-date loss of 18% compares unfavorably even against a peer group that is itself having a rough week.
The ORTEX short score of 30.4 — low and barely changed all week — confirms that the mechanics of the move are not short-driven. The next scheduled earnings event is October 22. Between now and then, the question the data leaves open is whether the distance between the consensus target of $115 and the current price of $86 narrows because the stock recovers, or because analysts begin to trim targets toward where the stock has already settled.
See the live data behind this article on ORTEX.
Open INTC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
